intravitreal rituximab

Overview

Intravitreal rituximab is an ophthalmic use of rituximab, a monoclonal anti-CD20 antibody, administered by injection into the vitreous cavity of the eye. In this setting, it is used as a local therapy to deliver B-cell–directed treatment directly to intraocular disease sites, rather than through systemic administration. Its principal biomedical relevance is in ocular conditions in which B-cell malignancy or immune-mediated pathology is present within the eye, especially vitreoretinal lymphoma.

As a localized route of administration, intravitreal rituximab is intended to achieve therapeutic exposure in ocular tissues while limiting systemic effects. In recent literature, it has been studied mainly as a salvage or adjunctive treatment in relapsed vitreoretinal lymphoma, including cases occurring after prior ocular radiotherapy.

Focus of Latest Publications

I need to flag a significant issue before proceeding: only one of the 13 abstracts provided actually mentions intravitreal rituximab — PMID 42200736 ("Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma").

The other 12 abstracts discuss systemic (intravenous) rituximab use in various conditions (lymphomas, cerebellar ataxia, membranous nephropathy, NMOSD, HSCT complications, glomerular diseases, infusion reactions). None of these mention intravitreal administration.

For PMID 42200736 specifically, the provided abstract contains only the study aims ("To describe the outcomes, response patterns, and complications..."), not the actual results, methods, or findings. Without the results section, I cannot substantively write about what was discovered.

To proceed, I need clarification:

1. Should I write based only on PMID 42200736, acknowledging that it's a single case study with limited detail?
2. Or was the abstract list intended to contain different papers where intravitreal rituximab was actually studied, and this was a selection error?
3. If 42200736 is correct, can you provide the full abstract with results and findings?

I can't write a credible "Focus of Latest Publications" section that invents findings or conflates intravitreal with systemic delivery — that would violate the "strictly based" requirement and accuracy standards for medical writing.

Key Publications

• NEWJul Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. (Anticancer research, 2026, PMID 42373284): "Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy has become a frontline treatment for diffuse large B-cell lymphoma (DLBCL), although evidence from patients aged >80 years remains limited."
• NEWJun Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report. (Cerebellum (London, England), 2026, PMID 42360526): "Rituximab was introduced as consolidation therapy after repeat first-line immunotherapy, while oral prednisone was tapered from 1 mg/kg/day to discontinuation in January 2026."
• NEWJun Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency. (NEJM evidence, 2026, PMID 42334299): "We hypothesized that B-cell depletion with rituximab could reverse autoimmune activity, enhance ovarian responsiveness to gonadotropins, and transiently restore fertility in autoimmune POI."
• NEWJun Pulmonary arterial hypertension from a translational perspective: Bridging pathophysiology and treatment. (Chinese medical journal, 2026, PMID 42311051): "Agents targeting the BMP/TGF-β axis (e.g., sotatercept), growth factor signaling (seralutinib), inflammatory pathways (tocilizumab, rituximab), and metabolic remodeling (pyruvate dehydrogenase kinases [PDK] and fatty acid oxidation [FAO] modulators) are redefining treatment paradigms."
• Jun The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis. (Annals of medicine, 2026, PMID 42247284): "Studies have shown that the efficacy of rituximab (RTX) in patients with M-type phospholipase A2 receptor (PLA2R)-associated primary membranous nephropathy (PMN) is related to proteinuria."
• Jun Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment. (Neurology, 2026, PMID 42224638): "We aim to determine annual spinal cord atrophy rates and influencing factors in NMOSD."
• Jun Pure Red Cell Aplasia Associated With Recipient B-Cell Mixed Chimerism Successfully Treated With Rituximab. (Pediatric transplantation, 2026, PMID 42216498): "Pure red cell aplasia (PRCA) is a rare but clinically significant complication of allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with major ABO incompatibility."
• May Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma. (Indian journal of ophthalmology, 2026, PMID 42200736): "To describe the outcomes, response patterns, and complications of intravitreal rituximab (IVR) in eyes with relapsed vitreoretinal lymphoma (VRL) despite previous treatment with ocular radiotherapy (EBRT)."
• Jun Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. (Pharmacology research & perspectives, 2026, PMID 42170767): "Rituximab is an anti-CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases."
• Jun Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial. (International journal of clinical oncology, 2026, PMID 41989666): "This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma."